预约演示
Addressing the next wave of COVID-19 through a new approach to vaccines
2023-02-20
疫苗信使RNA临床研究紧急使用授权引进/卖出
None
Ocugen, a fully integrated, patient-centric biotech company, is committed to developing gene and cell therapies to address unmet medical needs, and vaccines to positively impact public health. While the Company was founded on cutting-edge science for inherited retinal diseases, Co-Founder, CEO and Chair, Dr. Shankar Musunuri has spent over 30 years in biotech and half of that time in vaccines operations for one of the world’s leading pneumococcal vaccines. As such, he remains passionate about preventing life-threating diseases. When the world changed forever in 2020, there was no way Dr. Musunuri and his experienced leadership team were going to sit on the sidelines and wait for someone else to address the COVID-19 pandemic.
Ocugencugen’s R&D team and technical capabilities in place, the Company leveraged its network, and in 2021 licensed COVAXIN™ from Bharat Biotech for North American Markets. COVAXIN, a whole-virion inactivated COVID-19 vaccine candidate, applies the sainherited retinal diseases platform used in the production of polio vaccines for decades. COVAXIN is designed for a broad immune response with adult and pediatric Phase 2/3 data suggesting both humoral and cellular responses generated against multiple viral proteins. Data also support that the vaccine induces a Th1 response (cell-mediated immunity), which can be vital for durable protection.COVID-19 pandemic
COVAXOcugen provide an important additional vaccine option as a primary series or booster and to broaden the immune COVAXINe amongBharat Biotechho have been previously vacciCOVAXINith other U.S.- licensed vaccCOVID-19is vaccine is currently in late-stage trials in the U.S.polio vaccinesCOVAXIN
COVAXINOVAXIN offers a new option using a traditional platform, the fight against COVID-19 is entering a new phase as sequential mutations of the virus feature ever more transmissibility and immune-evading properties. For this reason, there is also a desperate need for next generation vaccines that provide protective immunity at the source of the infection and reduce the rate of transmission from one person to another. Mucosal vaccines have the potential to offer that type of protection.
LeaderCOVAXINe fields of epidemiology, public health, and vaccine development beliCOVID-19 a mucosal vaccine that provides immunity at the point of transmission and where COVID-19 is most lethal — the lungs — may be the most effective way to directly combat new variants. That’s why Ocugen obtained licensing rights from Washington University in St.infection develop a novel inhaled booster vaccine to be sold in the United States, Europe, Japan, and other major markets.
OCU500, Ocugen’s inhaled COVID-19 vaccine candidate, has the potential to generate rapid local immunity in the upper airways, and lungs—where both SARS-CoV-2 and seasonal COVID-19r and infect the body. This technology has been shown to generate neutralizing IgG, mucosal IgA, and T cOcugensponses to help reduce transmissWashington University in St. Louisn demonstrated as a potential way to prevent infection and spread, which contributes to the evolution of new variants. Furthermore, OCU500 represents a potential universal booster, regardless of previous COVID-19 vaccination.
OcuCOVID-19 vaccinesCOVID-19ursuing development of both COVAXIN and OCU500 to proOcugenew, safe and effective alternatives inOCU500ight against COVID-19. While billions of doses of vaccines have been delivered globally, vaccines that produce a more sustained response, suppress variants, and reduce transmission are still needed. As a recent editorial in the New England Journal of Medicine said, “Currently available vaccines have only modest effectiveness against mild infection and transmission, which is further reduced in the context of the newly emerging omicron subvariants. Hence, to slow down the circulation of the virus and to limit the speed at which further variants emerge, new vaccines that have a substantial effect on reducing mild infection and transmission are needed, even as the world attempts to learn how to live with SARS-CoV-2.”i
i Nohynek, Hanna and Annelies Wilder-Smith, “Does the World Still Need New Covid-19 Vaccines,” The New England Journal of Medicine, June 2, 2022, 386:2140-2142. https://www.nejm.org/doi/full/10.1056/NEJMe2204695
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。